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date. This study provides an estimate of the cost-effectiveness of
memantine compared with standard care (no pharmacotherapy)
in moderate to severe AD adapted to a Canadian setting and
including all available evidence. No other pharmacological treat-
ment was included in the evaluation as memantine is currently
the only drug approved in this indication. METHODS: The pro-
gression of AD in terms of cognitive severity, functional dis-
ability and mortality was simulated over two-years using a 
state-transition (Markov) model. Outcomes of the model were
Quality-Adjusted Life-Years (QALY) and costs from a societal
perspective. The main cost and epidemiological input parame-
ters of the model were computed using data from the Canadian
Study on Health and Aging (CSHA). All relevant published and
unpublished clinical trials of memantine versus placebo in mod-
erate to severe AD were used to compute the transition proba-
bilities between health states. A priori distributions were
associated to all relevant parameters in order to enable stochas-
tic analyses. RESULTS: Compared with standard care, the
memantine strategy produced 0.03 additional QALYs, with no
additional overall cost. Probabilistic sensitivity analyses give
83.3% chance that memantine treatment is cost neutral, 89.5%
chance of being cost-effective if the decision-maker is willing to
pay $20,000 for a quality-adjusted life year and 96.2% chance
for a willingness-to-pay of $100,000 per QALY. Robustness of
the results was conﬁrmed through one-way and scenario-based
sensitivity analyses. CONCLUSIONS: Our evaluation found
memantine dominant over standard care. Results were compa-
rable with those published for acetylcholinesterase inhibitors
indicated for treatment of earlier stages of AD.
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OBJECTIVE: To determine cost-effectiveness of antidepressant
groups (SNRIs, SSRIs, and TCAs) in treating major depressive
disorder (MDD) over a 6-month time horizon from the view-
point of the Brazilian Ministry of Health. METHODS: An exist-
ing decision tree model developed by our group was adapted to
Brazil, based on Brazilian treatment guidelines. Clinical data
were obtained from a published meta-analysis of remission rates
published by Machado et al. Patients included adults >= 18 with
MDD, diagnosed using DSM-III/IV or comparable, with moder-
ate-to-severe disease (HAMD >= 15 or MADRS >= 18), without
comorbidities or comedications, and followed by >= 6 weeks of
treatment. Treatments included: SNRIs (venlafaxine, duloxetine,
milnacipran), SSRIs (citalopram, escitalopram, ﬂuoxetine,
paroxetine, sertraline) and/or TCAs (clomipramine, amitripty-
line, nortriptyline, imipramine). SSRIs were used as secondary
treatment for SNRIs and TCAs, TCAs were used as secondary
treatment for SSRIs. Clinical outcome was remission, deﬁned as
a ﬁnal HAMD score <= 7 or MADRS <= 12. Included were all
direct costs of treatment (drug, physician visits, hospitalization).
Drug costs were obtained from the 2006 Brazilian National Drug
Price List. Costs of hospitalizations and physician visits were
taken from the 2006 Health care System database (DATASUS).
All costs were presented in undiscounted 2006 Brazilian Reais
(1R$ = USD$0.46). Univariate and Monte Carlo sensitivity
analyses were performed. RESULTS: The primary ITT remission
rate of SNRIs was signiﬁcantly (P < 0.05) higher than SSRIs and
TCAs. Expected costs/patient treated were: SNRIs = R$4698;
SSRIs = R$5341; TCAs = R$4867. Overall success rates (primary
+ secondary treatment across all decision tree branches) were:
SNRIs = 78.1%; SSRIs = 74.0%; TCAs = 76.4%. Average
costs/success were: SNRIs = R$6017; SSRIs = R$7217; TCAs =
$6368. Monte Carlo analysis conﬁrmed the relative positions.
Break-even analysis showed that results were sensitive to varia-
tions to primary success rates. CONCLUSIONS: SNRIs domi-
nated the other two antidepressant classes. Using SNRIs on
average could save the government R$775 million annually.
Further analyses are warranted to conﬁrm results since they were
sensitive to primary remission rates.
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OBJECTIVES: Economic models have demonstrated the cost-
effectiveness of escitalopram versus citalopram in major depres-
sive disorder (MDD), but no head-to-head clinical trials have
evaluated their cost-effectiveness to date. The objective of this
study was to assess the relative cost-effectiveness of escitalopram
compared with citalopram in outpatients with MDD.
METHODS: An economic evaluation was conducted alongside
a double-blind randomized clinical trial conducted by French
general practitioners and psychiatrists, comparing ﬁxed doses of
escitalopram (20 mg/day) or citalopram (40 mg/day) over 8
weeks in outpatients with MDD (baseline Montgomery-Åsberg
Depression Rating Scale (MADRS) score ≥30). A standardised
health care services form was used to record physician visits, hos-
pitalisations, treatments and days of sick leaves for the 2-month
pre-study period and the 8-week study period. RESULTS: Sta-
tistically signiﬁcant improvements in remission rates were
observed in patients treated with escitalopram (56% vs. 43%, 
p < 0.05). Using the price of the generic citalopram, mean per-
patient costs from a health care perspective for the escitalopram
group were 45% lower than the citalopram group (€79 vs. €144;
p < 0.05). Differences were mostly related to lower hospitalisa-
tion costs. Bootstrapped distributions of the cost-effectiveness
ratios also showed better effectiveness and lower costs for esci-
talopram compared with citalopram with more than 85% of 
the draws located in the southeastern quadrant of the cost-
effectiveness plan, indicating that escitalopram was the dominant
strategy. Sensitivity analyses conﬁrmed the dominance of esci-
talopram over citalopram from a payer perspective. CONCLU-
SIONS: Escitalopram is signiﬁcantly more effective than
citalopram and is associated with lower health care costs. This
prospective economic analysis demonstrated that escitalopram is
a cost-effective ﬁrst-line treatment option for MDD.
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OBJECTIVES: Despite progress in the treatment of schizophre-
nia following the introduction of atypical antipsychotics in the
late 1990s, current pharmacological options still carry limita-
tions, as highlighted in a recent, pragmatic study in the US.
Sertindole is an atypical antipsychotic with a good tolerability
proﬁle likely to favour long-term adherence, reductions in
relapse and re-hospitalisation rates, and improvements in overall
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functioning. METHODS: A Markov model was developed 
to estimate the cost-effectiveness of sertindole compared with
risperidone, olanzapine and aripiprazole in the management of
schizophrenia in Hungary over a two-year period. Patients
entered the model upon experiencing intolerance to their antipsy-
chotic treatment during an episode of acute psychopathology.
Confounding factors included drug-induced adverse events
(extrapyramidal symptoms, weight gain, sedation, sexual dys-
function, diabetes), compliance, relapse and treatment setting.
Effectiveness was deﬁned as the length of time without relapse
over the two-year evaluation period, and by Quality Adjusted
Life Years (QALYs). Parameter estimates were based upon pub-
lished literature and comparative clinical trial data. Resource use
data were obtained from the Psychiatry Department, Semmel-
weis University (Budapest), and costs were evaluated from the
Hungarian National Insurance perspective. RESULTS: The time
without relapse (over 2 years) for patients receiving sertindole
was equivalent to those with risperidone, olanzapine and arip-
iprazole (0.768, 0.768, 0.764 and 0.766, respectively). The
average cost per patient for two years after starting treatment
with sertindole equalled that of the other atypical antipsychotics.
The costs per year without relapse were similar for sertindole
treated patients compared with the atypical risperidone, olanza-
pine and aripiprazole treated patients (€15,435, 15,096, 15,925
and 15,712, respectively). Sensitivity analyses conﬁrmed robust-
ness of the model. CONCLUSIONS: With equivalent clinical
beneﬁts, a good tolerability proﬁle and similar costs, sertindole
is an additional valuable treatment alternative to other atypical
antipsychotics available in Hungary.
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OBJECTIVES: The aim of the study was to asses costs and effec-
tiveness of amisulpride and other atypical antipsychotic drugs for
the treatment of patients with schizophrenia in Poland.
METHODS: The cost-effectiveness analysis from the payer per-
spective was conducted. Clinical data was derived from pub-
lished clinical trials. Clinical improvement according to the Brief
Psychiatric Rating Scale (BPRS) was adopted as a measure of
effectiveness. Only direct medical costs were included and were
expressed in polish zloty (PLN), 1 EUR = 3.95 PLN, exchange
rate; 1 EUR = 1.98 PLN, purchasing power parities). The study
horizon amounted to 8 weeks (the short-term model) and to 6
months of treatment (the long-term model). In the analysis there
were three strategies of treatment compared: amisulpride,
risperidone and olanzapine. The comparison was done pair-
wisely: amisulpride vs olanzapine and amisulpride vs risperi-
done. RESULTS: Both in the short-term and in the long-term
model, the amisulpride proved to be a dominant strategy—
having lower average cost and higher average effect—against
risperidone as well as against olanzapine. Comparing 
amisulpride and risperidone—in the short-term model the cost-
effectiveness ratios (average cost per one unit of BPRS improve-
ment) amounted to 55.3 PLN and 83.1 PLN for amisulpride and
risperidone, respectively. In the long-term model the numbers
were 135.7 PLN and 179.3 PLN, respectively. Conducting the
amisulpride vs olanzapine comparison—in the short-term model
the cost-effectiveness ratios amounted to 34 PLN for amisulpride
and 43.5 PLN for olanzapine, and in the long-term model to:
105 PLN and 125 PLN, respectively. As amisulpride was a dom-
inant strategy in all comparisons, acceptability curves were 
calculated instead of incremental cost-effectiveness ratios. 
CONCLUSIONS: The pharmacoeconomic evaluation in the
short-term model as well as in the long-term model shows that
amisulpride is a dominant strategy in the treatment of schizo-
phrenia in Poland.
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OBJECTIVES: Olanzapine in fast dissolving orodispensable for-
mulation (OOT) was shown to be associated with greater patient
acceptance and improved medication adherence compared to
olanzapine in conventional tablet form (OCT) in acute treatment
settings. This study assessed, from a payer perspective, the cost
and effectiveness of OOT compared to OCT over a 1-year period
in the treatment of schizophrenia patients in Turkey.
METHODS: Survival Curve Model was used to assess the
dynamic effects of relapses and hospitalizations on direct cost of
treatment by considering medication efﬁcacy and patients’
adherence to the medication. Rates of relapse and rates of treat-
ment discontinuation—due to poor efﬁcacy, medication intoler-
ability, or patient preference/nonadherence—were based on
published medical literature, unpublished data, and a clinical
expert panel. The model assumed that treatment discontinuation
is lower with OOT compared with OCT in stabilized schizo-
phrenia patients. Model assumptions were validated by an inde-
pendent expert panel. RESULTS: Based on model projections,
the number of patients who would discontinue their current
medication during one year of treatment would be 28 for OOT
and 40 for OCT group. The number of predicted relapses was
15 for OOT and 18 for the OCT groups. Results indicate a 12%
increase in the number of patients who would continue their
therapy and 3% decrease in the number of relapses for the OOT
group. The projected annual total direct cost for a cohort of 
100 patients was 355.629,46 YTL for OOT treatment and
412.845,36 YTL for OCT treatment. If all patients were
assumed to be treated with OOT treatment instead of OCT, 16%
would be treated, without any additional cost to the payers in
Turkey. CONCLUSIONS: The use of olanzapine in fast dissolv-
ing orodispensable formulation is predicted in this model to be
more cost effective than olanzapine in conventional table form.
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OBJECTIVES: To estimate the cost-effectiveness of treatment
with long acting methylphenidate-OROS for youths with atten-
tion-deﬁcit hyperactivity disorder (ADHD) for whom treatment
with immediate-release (IR) methylphenidate is suboptimal.
METHODS: We developed a Markov model to obtain an incre-
